It is interesting that two drugs with the opposite mechanisms of action produce the same clinical response.
However, you might want to take the description of "reuptake enhancer" with a grain of salt. The mechanism of action (MOA) for drugs is notoriously difficult to determine.
The best example of this is Lyrica (Pfizer). The drug was designed to be a GABAase enzyme inhibitor (prevents GABA from being metabolized, increasing it's action). This MOA was pushed during the entire development of Lyrica. It wasn't until the drug hit the market that a researcher finally figured out that it works by modulating the glutamate neurotransmitter. It's effectiveness has nothing at all to do with GABA.
However, you might want to take the description of "reuptake enhancer" with a grain of salt. The mechanism of action (MOA) for drugs is notoriously difficult to determine.
The best example of this is Lyrica (Pfizer). The drug was designed to be a GABAase enzyme inhibitor (prevents GABA from being metabolized, increasing it's action). This MOA was pushed during the entire development of Lyrica. It wasn't until the drug hit the market that a researcher finally figured out that it works by modulating the glutamate neurotransmitter. It's effectiveness has nothing at all to do with GABA.